Zhifei Lin
Overview
Explore the profile of Zhifei Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan M, Chen Z, Shao W, Chen Y, Lin Z, Yi C, et al.
Acta Biochim Biophys Sin (Shanghai)
. 2023 Jul;
55(9):1479-1486.
PMID: 37434430
Lenvatinib has become the first-line therapy in advanced hepatocellular carcinoma (HCC), but its efficacy is still limited because of the inevitable development of resistance. It has been reported that cellular...
2.
Zhang B, Tao B, Li Y, Yi C, Lin Z, Ma Y, et al.
Eur J Intern Med
. 2023 Jan;
111:37-46.
PMID: 36588054
Background: Immune checkpoint inhibitor monotherapy did not show superiority of survival over standard therapy in advanced hepatocellular carcinoma. The combination immunotherapy including dual immune checkpoint inhibitors or combined with anti-VEGF...
3.
Sun R, Lin Z, Wang X, Liu L, Huo M, Zhang R, et al.
J Exp Clin Cancer Res
. 2022 Oct;
41(1):313.
PMID: 36280883
No abstract available.
4.
Sun R, Lin Z, Wang X, Liu L, Huo M, Zhang R, et al.
J Exp Clin Cancer Res
. 2022 Sep;
41(1):284.
PMID: 36163032
Background: Oxidative stress is a highly active metabolic process in the liver, that poses great threats to disseminated tumor cells during their colonization. Here, we aimed to investigate how colorectal...
5.
Ren X, Zhou Y, Luo Y, Wang C, Pan A, Ju Y, et al.
Gastroenterol Res Pract
. 2022 Apr;
2022:4589163.
PMID: 35432524
Interleukin-6 (IL-6), an important inflammatory cytokine, is a key factor regulating cancer metastasis. Cancer cells can modulate their tumorigenic abilities by sorting specific microRNAs (miRNAs) as exosomes into the tumor...
6.
Zhang B, Chen Z, Tao B, Yi C, Lin Z, Li Y, et al.
Mol Cancer
. 2021 Dec;
20(1):170.
PMID: 34930277
Recent studies have revealed the significant dysregulation of mA level in peripheral blood in several cancer types and its value in diagnosis. Nonetheless, a biomarker for accurate screening of multiple...
7.
Chen J, Lin Z, Liu L, Zhang R, Geng Y, Fan M, et al.
Signal Transduct Target Ther
. 2021 Nov;
6(1):397.
PMID: 34795203
The immunosuppressive microenvironment plays an important role in tumor progression and immunotherapy responses. Golgi membrane protein 1 (GOLM1) is correlated to hepatocellular carcinoma (HCC) progression and metastasis. However, little is...
8.
Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, et al.
Hepatology
. 2021 May;
74(5):2544-2560.
PMID: 34036623
Background And Aims: Recently, clinical trials of lenvatinib plus pembrolizumab in HCC have displayed an impressive objective response rate. This study aimed to clarify the mechanism for optimal patient selection....
9.
Zheng Y, Huang C, Lu L, Yu K, Zhao J, Chen M, et al.
J Hematol Oncol
. 2021 Jan;
14(1):16.
PMID: 33446239
Background: Dysregulation of both mitochondrial biogenesis and mitophagy is critical to sustain oncogenic signaling pathways. However, the mechanism of mitophagy in promoting hepatocellular carcinoma (HCC) progression remains poorly understood. In...
10.
Shao W, Zhu W, Lin J, Luo M, Lin Z, Lu L, et al.
Neoplasia
. 2019 Nov;
22(1):1-9.
PMID: 31751859
Sorafenib is the first approved systemic therapy for advanced hepatocellular carcinoma (HCC) and is the first-line choice in clinic. Sustained activation of receptor tyrosine kinases (RTKs) is associated with low...